SEC Contract Filing

Filing Date: 2025-01-30

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ea022913501ex10-1_drugs.htm
<DESCRIPTION>LETTER AGREEMENT, DATED JANUARY 7, 2025, BY AND AMONG THE COMPANY, DRUGS MADE IN AMERICA ACQUISITION LLC, THE INITIAL SHAREHOLDERS AND THE OFFICERS AND DIRECTORS OF THE COMPANY
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LETTER AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated January 7, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This letter agreement (this
&ldquo;<B>Letter Agreement</B>&rdquo;) is entered into by and among Drugs Made In America Acquisition Corp., a Cayman Islands exempted
company (the &ldquo;<B>Company</B>&rdquo;), Drugs Made In America Acquisition LLC, a Delaware limited liability company (the &ldquo;<B>Sponsor</B>&rdquo;),
and each other undersigned person (each such other undersigned person, an &ldquo;<B>Insider</B>&rdquo; and collectively, the &ldquo;<B>Insiders</B>&rdquo;).
Reference is made to that certain underwriting agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) entered into or proposed to
be entered into by and between the Company and Clear Street <FONT STYLE="font-family: Times New Roman, Times, Serif">LLC</FONT>, as representative
of the underwriters (the &ldquo;<B>Representative</B>&rdquo;), relating to an underwritten initial public offering (the &ldquo;<B>Public
Offering</B>&rdquo;), of up to 20,000,000 of the Company&rsquo;s units (including up to 3,000,000 units that may be purchased to cover
the underwriters&rsquo; option to purchase additional units, if any) (the &ldquo;<B>Units</B>&rdquo;), each comprised of one ordinary
share of the Company, par value $0.0001 per share (&ldquo;<B>Ordinary Share</B>&rdquo;), and one right to receive one-eighth (1/8) of an ordinary
share upon the consummation of an initial business combination (each whole right, a &ldquo;<B>Right</B>&rdquo;). The Units shall be sold
in the Public Offering pursuant to a registration statement on Form S-1 and prospectus (the &ldquo;<B>Prospectus</B>&rdquo;) filed by
the Company with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;). Certain capitalized terms used herein
are defined in paragraph 12 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to induce the Company
and the Representative to enter into the Underwriting Agreement and to proceed with the Public Offering and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Sponsor and the Insiders each hereby agrees, severally
but not jointly, with the Company as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1. The
Sponsor and each Insider agrees that if the Company seeks shareholder approval of a proposed Business Combination, then in connection
with such proposed Business Combination, it, he or she shall (i) vote any Shares (as defined below) owned by it, him or her in favor of
any proposed Business Combination (including any proposals recommended by the Company&rsquo;s board of directors in connection with such
Business Combination) and (ii) not redeem any Shares owned by it, him or her in connection with such shareholder approval.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2. The
Sponsor and each Insider hereby agrees that in the event that the Company fails to consummate a Business Combination within 15 months
from the closing of the Public Offering (subject to extension as provided the Company&rsquo;s second amended and restated memorandum and
articles of association (as may be amended and/or restated from time to time, the &ldquo;<B>Articles</B>&rdquo;)) (the time period the
Company has to complete a Business Combination, as it may be extended, the &ldquo;<B>completion window</B>&rdquo;), or such later period
approved by the Company&rsquo;s shareholders in accordance with the Articles, the Sponsor and each Insider shall take all reasonable steps
to cause the Company to (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not
more than ten (10) business days thereafter, subject to lawfully available funds therefor, redeem 100% of the Ordinary Shares sold as
part of the Units in the Public Offering (the &ldquo;<B>Offering Shares</B>&rdquo;), at a per share price, payable in cash, equal to the
aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable and less up to
$100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding Offering Shares, which redemption
will completely extinguish all Public Shareholders&rsquo; rights as shareholders (including the right to receive further liquidation distributions,
if any) and (iii) as promptly as reasonably possible following such redemption